An estimated 3.6 million Medicare beneficiaries could potentially access Wegovy now that the Food and Drug Administration (FDA) approved the drug for reducing the risk of incidents related to cardiovascular disease. A KFF analysis found that among the 13.7 million people on Medicare diagnosed with obesity, 3.6 million, or roughly 1 in 4, of these beneficiaries also have diagnoses of cardiovascular disease. These potential beneficiaries represent about 7 percent of all those on Medicare. These findings are based on data from 2020. Wegovy is a form of semaglutide, also sold as the diabetes treatment Ozempic. As GLP-1 agonist, it is among the class of drugs that have until recently
Hence then, the article about 1 in 4 medicare beneficiaries with obesity could get wegovy despite coverage ban was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( 1 in 4 Medicare beneficiaries with obesity could get Wegovy despite coverage ban )